The FDA has approved Jazz Pharmaceuticals and Zymeworks’s HER2 × HER2 bispecific antibody, for HER2-positive biliary tract cancer (BTC). The antibody, called zanidatamab (Ziihera), validates ...

Bispecific antibodies seem to be all the rage at the minute. Their ability to deliver targeted therapeutics to patients with a two-in-one approach by simultaneously binding to two different antigens ...